Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

Mise à jour : Il y a 4 ans
Référence : NCT00440622

Femme Homme

  • | Pays :
  • Greece
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The optimal treatment for pretreated patients with metastatic breast cancer has not been established. Gemcitabine and capecitabine are two active agents in this setting. For women with Her-2 positive breast cancer, combinations of either gemcitabine or capecitabine (Xeloda) plus Herceptin has been proved active and well tolerated.


Critère d'inclusion

  • Breast Cancer

Liens